Violation Tracker Individual Record

Company: 
TAP Pharmaceutical Products Inc.
Current Parent Company: 
Takeda Pharmaceutical
Penalty: 
$875,000,000
Year: 
2001
Date: 
October 3, 2001
Offense Group: 
government-contracting-related offenses
Primary Offense: 
False Claims Act and related
Secondary Offense: 
fraud
Violation Description: 

TAP Pharmaceutical agreed to pay a total of $875 million to resolve a case involving fraudulent pricing and improper marketing of its prostate cancer drug Lupron. The amount included a $290 million criminal fine for violating the Prescription Drug Marketing Act; a $559.5 million False Claims Act civil settlement ; and $25.5 million in payments to state governments. TAP was formerly a joint venture of Takeda Pharmaceutical and Abbott Laboratories; the companies dissolved the venture in 2008, and Takeda took over most of its operations.

Level of Government: 
federal
Action Type: 
agency action
Agency: 
Justice Department Civil Division
Civil or Criminal Case: 
civil and criminal
HQ Country of Parent: 
Japan
Ownership Structure of Parent: 
publicly traded
Major Industry of Parent: 
pharmaceuticals
Specific Industry of Parent: 
pharmaceuticals
Source Notes: 
If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Parent company note: 
Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.